CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM016242
Első szerző:Dubois, Patrick C. A.
Cím:Multiple common variants for celiac disease influencing immune gene expression / Dubois Patrick C. A., Trynka Gosia, Franke Lude, Hunt Karen A., Romanos Jihane, Curtotti Alessandra, Zhernakova Alexandra, Heap Graham A. R., Ádány Róza, Aromaa Arpo, Bardella Maria Teresa, van den Berg Leonard H., Bockett Nicholas A., de la Concha Emilio G., Dema Bárbara, Fehrmann Rudolf S. N., Fernández-Arquero Miguel, Fiatal Szilvia, Grandone Elvira, Green Peter M., Groen Harry J. M., Gwilliam Rhian, Houwen Roderick H. J., Hunt Sarah E., Kaukinen Katri, Kelleher Dermot, Korponay-Szabo Ilma, Kurppa Kalle, MacMathuna Padraic, Mäki Markku, Mazzilli Maria Cristina, McCann Owen T., Mearin M. Luisa, Mein Charles A., Mirza Muddassar M., Mistry Vanisha, Mora Barbara, Morley Katherine I., Mulder Chris J., Murray Joseph A., Núnez Concepción, Oosterom Elvira, Ophoff Roel A., Polanco Isabel, Peltonen Leena, Platteel Mathieu, Rybak Anna, Salomaa Veikko, Schweizer Joachim J., Sperandeo Maria Pia, Tack Greetje J., Turner Graham, Veldink Jan H., Verbeek Wieke H. M., Weersma Rinse K., Wolters Victorien M., Urcelay Elena, Cukrowska Bozena, Greco Luigi, Neuhausen Susan L., McManus Ross, Barisani Donatella, Deloukas Panos, Barrett Jeffrey C., Saavalainen Paivi, Wijmenga Cisca, van Heel David A.
Dátum:2010
ISSN:1061-4036
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Nature Genetics. - 42 : 4 (2010), p. 295-302. -
További szerzők:Trynka, Gosia Franke, Lude Hunt, Karen A. Romanos, Jihane Curtotti, Alessandra Zhernakova, Alexandra Heap, Graham A. R. Ádány Róza (1952-) (megelőző orvostan és népegészségtan szakorvos) Aromaa, Arpo Bardella, Maria Teresa Van den Berg, Leonard H. Bockett, Nicholas A. Concha, Emilio G., de la Dema, Bárbara Fehrmann, Rudolf S. N. Fernández-Arquero, Miguel Fiatal Szilvia (1978-) (epidemiológus, népegészségügyi szakember) Grandone, Elvira Green, Peter M. Groen, Harry J. M. Gwilliam, Rhian Houwen, Roderick H. J. Hunt, Sarah E. Kaukinen, Katri Kelleher, Dermot Korponay-Szabó Ilma (1959-) (gyermekgyógyász) Kurppa, Kalle MacMathuna, Padraic Mäki, Markku Mazzilli, Maria Cristina McCann, Owen T. Mearin, Maria Luisa Mein, Charles A. Mirza, Muddassar M. Mistry, Vanisha Mora, Barbara Morley, Katherine I. Mulder, Chris J. Murray, Joseph A. Núnez, Concepción Oosterom, Elvira Ophoff, Roel A. Polanco, Isabel Peltonen, Leena Platteel, Mathieu Rybak, Anna Salomaa, Veikko Schweizer, Joachim J. Sperandeo, Maria Pia Tack, Greetje J. Turner, Graham Veldink, Jan H. Verbeek, Wieke H. M. Weersma, Rinse K. Wolters, Victorien M. Urcelay, Elena Cukrowska, Bozena Greco, Luigi Neuhausen, Susan L. McManus, Ross Barisani, Donatella Deloukas, Panos Barrett, Jeffrey C. Saavalainen, Päivi Wijmenga, Cisca Heel, David A., van
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM048562
Első szerző:Tack, Greetje J.
Cím:Consumption of gluten with gluten-degrading enzyme by celiac patients : a pilot-study / Greetje J. Tack, Jolanda M. W. van de Water, Maaike J. Bruins, Engelina M. C. Kooy-Winkelaar, Jeroen van Bergen, Petra Bonnet, Anita C. E. Vreugdenhil, Ilma Korponay-Szabo, Luppo Edens, B. Mary E. von Blomberg, Marco W. J. Schreurs, Chris J. Mulder, Frits Koning
Dátum:2013
ISSN:1007-9327
Megjegyzések:AIM:To assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN-PEP) to mitigate the immunogenic effects of gluten in celiac patients.METHODS:Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet (GFD) resulting in normalised antibodies and mucosal healing classified as Marsh 0 or I were included. In a randomised double-blind placebo-controlled pilot study, patients consumed toast (approximately 7 g/d gluten) with AN-PEP for 2 wk (safety phase). After a 2-wk washout period with adherence of the usual GFD, 14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk (efficacy phase). Measurements at baseline included complaints, quality-of-life, serum antibodies, immunophenotyping of T-cells and duodenal mucosa immunohistology. Furthermore, serum and quality of life questionnaires were collected during and after the safety, washout and efficacy phase. Duodenal biopsies were collected after the safety phase and after the efficacy phase. A change in histological evaluation according to the modified Marsh classification was the primary endpoint.RESULTS:In total, 16 adults were enrolled in the study. No serious adverse events occurred during the trial and no patients withdrew during the trial. The mean score for the gastrointestinal subcategory of the celiac disease quality (CDQ) was relatively high throughout the study, indicating that AN-PEP was well tolerated. In the efficacy phase, the CDQ scores of patients consuming gluten with placebo or gluten with AN-PEP did not significantly deteriorate and moreover no differences between the groups were observed. During the efficacy phase, neither the placebo nor the AN-PEP group developed significant antibody titers. The IgA-EM concentrations remained negative in both groups. Two patients were excluded from entering the efficacy phase as their mucosa showed an increase of two Marsh steps after the safety phase, yet with undetectable serum antibodies, while 14 patients were considered histologically stable on gluten with AN-PEP. Also after the efficacy phase, no significant deterioration was observed regarding immunohistological and flow cytometric evaluation in the group consuming placebo compared to the group receiving AN-PEP. Furthermore, IgA-tTG deposit staining increased after 2 wk of gluten compared to baseline in four out of seven patients on placebo. In the seven patients receiving AN-PEP, one patient showed increased and one showed decreased IgA-tTG deposits.CONCLUSION:AN-PEP appears to be well tolerated. However, the primary endpoint was not met due to lack of clinical deterioration upon placebo, impeding an effect of AN-PEP.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Adverse events
Aspergillus niger prolyl endoprotease
Celiac disease
Enzyme
IgA-tTG intestinal deposits
Prolyl endoprotease
Megjelenés:World Journal of Gastroenterology 19 : 35 (2013), p. 5837-5847. -
További szerzők:Water, Jolanda M. W. van de Bruins, Maaike J. Kooy-Winkelaar, Engelina M. C. Bergen, Jeroen van Bonnet, Petra Vreugdenhil, Anita C. E. Korponay-Szabó Ilma (1959-) (gyermekgyógyász) Edens, Luppo Blomberg, B. Mary E. von Schreurs, Marco W. J. Mulder, Chris J. Koning, Frits
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1